Cited by 177Lipoproteins and Cardiovascular HealthNitric Oxide and Endothelin EffectsCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function

Open access

Wassmann, Sven, Faul, Anna, Hennen, Benno, Scheller, Bruno, Böhm, Michael, Nickenig, Georg·2003·Circulation Research

DOI 10.1161/01.res.0000099503.13312.7b

Open this paper in CoChat — free account Open PDF

Abstract

Treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decreases cardiovascular event rates in hypercholesterolemic patients. Whether statins exert effects within 24 hours on the coronary vasculature in patients with endothelial dysfunction has not been elucidated. Twenty-seven patients with stable angina pectoris and average low-density lipoprotein cholesterol concentrations of 138±9 mg/dL at baseline were allocated to treatment with placebo (14 patients) or 40 mg/d pravastatin (13 patients) in a randomized, double-blind, prospective trial. Coronary endothelial function was assessed before and 24 hours after single treatment by quantitative coronary angiography during intracoronary infusion of nitroglycerin or increasing concentrations of acetylcholine (0.01, 0.1, and 1 μmol/L). Coronary blood flow reserve was measured by Doppler velocimetry during adenosine infusion. Intracoronary acetylcholine infusion induced abnormal vasoconstriction in both groups before treatment, indicating coronary endothelial dysfunction. Treatment with a single oral 40-mg dose of pravastatin significantly attenuated acetylcholine-mediated vasoconstriction after 24 hours (mean±SE decrease in luminal diameter before and after treatment: 0.01 μmol/L, 6.1±2.2% versus 3.0±1.2%; 0.1 μmol/L, 15.6±2.6% versus 7.4±1.8%; P <0.05; 1 μmol/L, 22.9±2.9% versus 13.2±2.6%; P <0.05). There was no significant difference in the response to acetylcholine in the placebo group (8.1±2.4% versus 9.7±2.4%, 16.1±2.9% versus 16.8±3.2%, and 21.4±3.9% versus 23.3±4.2%). The response to nitroglycerin infusion was not altered in both groups. Increase in coronary blood flow in response to adenosine and coronary flow reserve remained unchanged during placebo and statin treatment. Serum concentrations of blood lipids and high-sensitive C-reactive protein were not significantly altered after 24 hours in response to placebo or pravastatin therapy. Statin treatment improves endothelium-dependent coronary vasomotion within 24 hours in the absence of significant cholesterol reduction. The full text of this article is available online at http://www.circresaha.org.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.res.0000099503.13312.7b

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease
Schächinger, V., Britten, M. B., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.101.16.1899 · Cited by 2,589
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Long-Term Follow-Up of Patients With Mild Coronary Artery Disease and Endothelial Dysfunction
Suwaidi, J. M. S. A., Hamasaki, S., Higano, S. T., Nishimura, R. A., Holmes, D. R., & Lerman, A. (2000) · Circulation · doi:10.1161/01.cir.101.9.948 · Cited by 2,044

Show all 41 references

Research works printed but not linked: 14

10.1161/atvb.21.11.1712 · DOI
10.1161/circ.89.6.8205659 · DOI
10.1161/circ.101.16.1899 · DOI
10.1161/circ.101.9.948 · DOI
10.1161/circ.104.22.2673 · DOI
10.1161/circ.104.4.376 · DOI
10.1161/circ.95.5.1126 · DOI
10.1161/circ.97.12.1129 · DOI
10.1161/circ.105.8.933 · DOI
10.1161/atvb.22.2.300 · DOI
10.1161/atvb.20.1.61 · DOI
10.1161/atvb.21.1.122 · DOI
10.1161/circ.95.1.76 · DOI
10.1161/circ.100.3.230 · DOI

Sorted by citations

Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention
Patti, G., Pasceri, V., Colonna, G., Miglionico, M., Fischetti, D., Sardella, G., Montinaro, A., & Sciascio, G. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.025 · Cited by 483
Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention
Pasceri, V., Patti, G., Nusca, A., Pristipino, C., Richichi, G., & Sciascio, G. D. (2004) · Circulation · doi:10.1161/01.cir.0000137828.06205.87 · Cited by 466
Simvastatin Versus Ezetimibe
Landmesser, U., Bahlmann, F. H., Mueller, M., Spiekermann, S., Kirchhoff, N., Schulz, S., Manes, C., Fischer, D., de Groot, K., Fliser, D., et al. (2005) · Circulation · doi:10.1161/01.cir.0000164260.82417.3f · Cited by 423
Circulating CD31 + /Annexin V + Apoptotic Microparticles Correlate With Coronary Endothelial Function in Patients With Coronary Artery Disease
Werner, N., Waßmann, S., Ahlers, P., Kosiol, S., & Nickenig, G. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191634.13057.15 · Cited by 339
Self-citation
Effect of Atorvastatin and Irbesartan, Alone and in Combination, on Postprandial Endothelial Dysfunction, Oxidative Stress, and Inflammation in Type 2 Diabetic Patients
Ceriello, A., Assaloni, R., Da Ros, R., Maier, A., Piconi, L., Quagliaro, L., Esposito, K., & Giugliano, D. (2005) · Circulation · doi:10.1161/01.cir.0000165070.46111.9f · Cited by 298
The vulnerable atherosclerotic plaque
Aikawa, M., & Libby, P. (2004) · Cardiovascular Pathology · doi:10.1016/s1054-8807(04)00004-3 · Cited by 242
Insulin resistance and the endothelium
Hsueh, W. A., Lyon, C. J., & Quiñones, M. J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.042 · Cited by 236
Optimized Treatment of ST-Elevation Myocardial Infarction
Niccoli, G., Montone, R. A., Ibáñez, B., Thiele, H., Crea, F., Heusch, G., Bulluck, H., Hausenloy, D. J., Berry, C., Stiermaier, T., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315344 · Cited by 227
Beyond the Laboratory
Halcox, J., & Deanfield, J. E. (2004) · Circulation · doi:10.1161/01.cir.0000129500.29229.92 · Cited by 200
Targeting Rho and Rho-kinase in the treatment of cardiovascular disease
Budzyn, K., Marley, P. D., & Sobey, C. G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.12.002 · Cited by 194
Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention
Patti, G., Cannon, C. P., Murphy, S. A., Mega, S., Pasceri, V., Briguori, C., Colombo, A., Yun, K. H., Jeong, M. H., Kim, J., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.002451 · Cited by 188
Efficacy of High-Dose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction
Kim, J.-S., Kim, J., Choi, D., Lee, C. J., Lee, S. H., Ko, Y.-G., Hong, M.-K., Kim, B.-K., Oh, S. J., Jeon, D. W., et al. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.11.021 · Cited by 183
Prevention of radiocontrast medium–induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial—a randomized controlled study
Jo, S., Koo, B., Park, J., Kang, H., Cho, Y., Kim, Y.-J., Youn, T., Chung, W., Chae, I., Choi, D., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.11.042 · Cited by 177
Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study
Cavallini, D., Bedani, R., Bomdespacho, L. D. Q., Vendramini, R. C., & Rossi, E. A. (2009) · Lipids in Health and Disease · doi:10.1186/1476-511x-8-1 · Cited by 165
Treating influenza with statins and other immunomodulatory agents
Fedson, D. S. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.06.018 · Cited by 162
Pandemic Influenza: A Potential Role for Statins in Treatment and Prophylaxis
Fedson, D. S. (2006) · Clinical Infectious Diseases · doi:10.1086/505116 · Cited by 157
The clinical significance of endothelial dysfunction
Landmesser, U., & Drexler, H. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000179821.11071.79 · Cited by 142
Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy
Fichtlscherer, S., Schmidt‐Lucke, C., Bojunga, S., Rössig, L., Heeschen, C., Dimmeler, S., & Zeiher, A. M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi881 · Cited by 140
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139
Statin use is associated with lower disease severity in COVID-19 infection
Tan, W. Y. T., Young, B. E., Lye, D. C., Chew, D. E. K., & Dalan, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74492-0 · Cited by 107
Antioxidative effects of statins
Adam, O., & Laufs, U. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0344-4 · Cited by 99
Atherogenesis: the role of inflammation and infection
Mahmoudi, M., Curzen, N. P., & Gallagher, P. J. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02503.x · Cited by 99
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia
Puccetti, L., Santilli, F., Pasqui, A. L., Lattanzio, S., Liani, R., Ciani, F., Ferrante, E., Ciabattoni, G., Scarpini, F., Ghezzi, A. R., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.006 · Cited by 89
Efficacy of Short-Term High-Dose Atorvastatin for Prevention of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography
Özhan, H., Erden, İ., Ordu, S., Aydın, M., Çağlar, O., Başar, C., Yalçin, S., & Alemdar, R. (2010) · Angiology · doi:10.1177/0003319710364216 · Cited by 89
Integrins and proximal signaling mechanisms in cardiovascular disease
Lal, H. (2009) · Frontiers in bioscience · doi:10.2741/3381 · Cited by 86
Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial
Berwanger, O. B., Silva, P. G. M. D. B. E., Barbosa, R. R., Précoma, D. B., Figueiredo, E. L., Hajjar, L. A., Kruel, C. D. P., Alboim, C., Almeida, A. P., Dracoulakis, M. D. A., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.11.001 · Cited by 75
Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Adam, O., Neuberger, H., Böhm, M., & Laufs, U. (2008) · Circulation · doi:10.1161/circulationaha.107.760892 · Cited by 73
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: Results of the CEZAR study
Ostad, M. A., Eggeling, S., Tschentscher, P., Schwedhelm, E., Böger, R. H., Wenzel, P., Meinertz, T., Münzel, T. F., & Warnholtz, A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.11.032 · Cited by 74
GCG‐Rich Tea Catechins are Effective in Lowering Cholesterol and Triglyceride Concentrations in Hyperlipidemic Rats
Lee, S. M., Kim, C. W., Kim, J. K., Shin, H. J., & Baik, J. H. (2008) · Lipids · doi:10.1007/s11745-008-3167-4 · Cited by 67
The Nonlipid Effects of Statins on Endothelial Function
Beckman, J. A., & Creager, M. A. (2006) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2006.03.003 · Cited by 67
Neuroprotection by pravastatin in acute ischemic stroke in rats
Berger, C., Feng, X., Maurer, M. H., & Schwab, S. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.10.010 · Cited by 66
Models to Study Atherosclerosis: A Mechanistic Insight
Singh, V., Tiwari, R. L., Dikshit, M., & Barthwal, M. K. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109787354097 · Cited by 65
Airway smooth muscle as a target of asthma therapy: history and new directions
Janssen, L. J., & Killian, K. J. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-123 · Cited by 63
Rosuvastatin Reduces Platelet Activation in Heart Failure
Schäfer, A., Fraccarollo, D., Eigenthaler, M., Tas, P. W. L., Firnschild, A., Frantz, S., Ertl, G., & Bauersachs, J. K. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000161926.43967.df · Cited by 61
HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration?
Guymer, R. H., Chiu, A. W.-I., Lim, L. L., & Baird, P. N. (2005) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2004.12.002 · Cited by 61
The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials
Tabrizi, R., Tamtaji, O. R., Mirhosseini, N. Z., Lankarani, K. B., Akbari, M., Dadgostar, E., Borhani‐Haghighi, A., Peymani, P., Ahmadizar, F., & Asemi, Z. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.010 · Cited by 58
Statins: another class of antihypertensive agents?
Milionis, H. J., Liberopoulos, E. N., Achimastos, A. D., Elisaf, M., & Mikhailidis, D. P. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002001 · Cited by 57
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology
Ray, K. K., & Cannon, C. P. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200412000-00003 · Cited by 57
Endothelial Nitric Oxide Synthase Gene: Prospects for Treatment of Heart Disease
Cooke, G. E., Doshi, A. A., & Binkley, P. F. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.12.1723 · Cited by 55
Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Hahn, J., Kim, H.-J., Choi, Y. J., Jo, S., Kim, H. J., Lee, S., Ahn, K.-J., Song, Y. B., Choi, J., Choi, S., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.011 · Cited by 56
Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins
Mason, R. P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.018 · Cited by 56
Targeting Nitric Oxide With Drug Therapy
Mason, R. P., & Cockcroft, J. R. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.06041.x · Cited by 54
Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats
Sun, X., & Ku, D. D. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01112.2007 · Cited by 52
Preoperative statin use and outcomes following cardiac surgery
Ali, I. S., & Buth, K. J. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.06.006 · Cited by 52
Antioxidant Effects of Statins in the Management of Cardiometabolic Disorders
Lim, S. K., & Barter, P. J. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.24398 · Cited by 53
Early Effects of Simvastatin versus Atorvastatin on Oxidative Stress and Proinflammatory Cytokines in Hyperlipidemic Subjects
Marketou, M. E., Zacharis, E. A., Nikitovic, D., Ganotakis, E. S., Parthenakis, F. I., Maliaraki, N. E., & Vardas, P. E. (2006) · Angiology · doi:10.1177/000331970605700212 · Cited by 49
Statin Therapy in Metabolic Syndrome and Hypertension Post-JUPITER: What is the Value of CRP?
Devaraj, S., Siegel, D., & Jialal, I. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0143-2 · Cited by 49
Coronary Microvascular Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Artery Disease Is Associated With Elevated Serum Homocysteine Levels
Ahmad, A., Corban, M., Toya, T., Sara, J. D. S., Lerman, B., Park, J. Y., Lerman, L. O., & Lerman, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017746 · Cited by 45
Simvastatin May Improve Myocardial Perfusion Abnormality in Slow Coronary Flow
Çakmak, M., Tanriverdi, H. I., Çakmak, N., Evrengül, H., Albeyoğlu, Ş., & Kuru, Ö. (2007) · Cardiology · doi:10.1159/000109405 · Cited by 45
Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina
Karatzis, E. N., Lekakis, J. P., Papamichael, C. M., Andreadou, I., Cimponeriu, A., Aznaouridis, K. A., Papaioannou, T., Protogerou, A. D., & Mavrikakis, M. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.03.060 · Cited by 44
Endothelial function, arterial stiffness and lipid lowering drugs
Τζιόμαλος, Κ., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1143 · Cited by 41
Endothelial Function in the Forearm Circulation of Patients with the Metabolic Syndrome – Effect of Different Lipid-Lowering Regimens
Bulut, D., Hanefeld, C., Bulut-Streich, N., Graf, C., Mügge, A., & Spiecker, M. (2005) · Cardiology · doi:10.1159/000088105 · Cited by 41
A Pharmacogenetics‐based Approach to Reduce Cardiovascular Mortality with the Prophylactic Use of Statins
Lacchini, R., Silva, P. S., & Tanus-Santos, J. E. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00551.x · Cited by 41
Pitavastatin, an HMG-CoA Reductase Inhibitor, Ameliorates Endothelial Function in Chronic Smokers
Yoshida, O., Kondo, T., Kureishi-Bando, Y., Sugiura, T., Maeda, K., Okumura, K., & Murohara, T. (2009) · Circulation Journal · doi:10.1253/circj.cj-09-0345 · Cited by 40
Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins
Asselbergs, F. W., van der Harst, P., Jessurun, G. A. J., Tio, R. A., & van Gilst, W. H. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.01.009 · Cited by 40
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors
Rodrı́guez, C., Alcudia, J. F., Martínez‐González, J., Guadall, A., Raposo, B., Sánchez-Gómez, S., & Badimón, L. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp136 · Cited by 40
Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels
Schneider, M. P., Schmidt, B. M. W., John, S., & Schmieder, R. E. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834a509a · Cited by 37
Insulin resistance and the endothelium
Quiñones, M. J., Nicholas, S. B., & Lyon, C. J. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0018-z · Cited by 35
Preoperative Statin Therapy Does Not Reduce Cognitive Dysfunction After Cardiopulmonary Bypass
Mathew, J. P., Grocott, H. P., McCurdy, J. R., Ti, L. K., Davis, R. D., Laskowitz, D. T., Podgoreanu, M. V., Swaminathan, M., Lynch, J., Stafford‐Smith, M., et al. (2005) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2005.03.004 · Cited by 34
Pleiotropic Effects With Equivalent Low-density Lipoprotein Cholesterol Reduction: Comparative Study Between Simvastatin and Simvastatin/Ezetimibe Coadministration
de Araújo, D. B., Bertolami, M. C., Ferreira, W. P., Abdalla, D. S. P., Faludi, A. Á., Nakamura, Y., & Bricharello, L. P. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181bfb1a2 · Cited by 33
Acute activation of eNOS by statins involves scavenger receptor‐B1, G protein subunit Gi, phospholipase C and calcium influx
Datar, R. A., Kaesemeyer, W., Chandra, S., Fulton, D. J., & Caldwell, R. B. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00817.x · Cited by 33
Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
Marenzi, G., Cosentino, N., Cortinovis, S., Milazzo, V., Rubino, M., Cabiati, A., Metrio, M. D., Moltrasio, M., Lauri, G., Campodonico, J., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.016 · Cited by 32
Acute Effect of Atorvastatin on Coronary Circulation Measured by Transthoracic Doppler Echocardiography in Patients Without Coronary Artery Disease by Angiography
Hinoi, T., Matsuo, S., Tadehara, F., Tsujiyama, S., & Yamakido, M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.02.050 · Cited by 32
Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions
Liu, Y.-H., Liu, Y., Duan, C., Tan, N., Chen, J., Zhou, Y., Li, L., & He, P. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414549462 · Cited by 32
Abnormal Vasoconstrictor Responses to Angiotensin II and Noradrenaline in Isolated Small Arteries From Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Hussain, M. B., Singhal, S., Markus, H. S., & Singer, D. R. J. (2004) · Stroke · doi:10.1161/01.str.0000120730.54282.a0 · Cited by 31
Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
Liu, Y., Liu, Y.-H., Tan, N., Chen, J., Zhou, Y., Li, L., Duan, C., Chen, P., Luo, J., Li, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111124 · Cited by 31
HMG-CoA Reductase Inhibitors in Chronic Heart Failure
Laufs, U., Custodis, F., & B�hm, M. (2006) · Drugs · doi:10.2165/00003495-200666020-00002 · Cited by 31
Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis
Zhang, F., Dong, L., & Ge, J. (2010) · Annals of Medicine · doi:10.3109/07853890903463976 · Cited by 30
Effects of perioperative statins on patient outcomes after noncardiac surgery: a meta-analysis
Ma, B., Sun, J., Diao, S., Zheng, B., & Li, H. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1471217 · Cited by 30
Nonlipid-lowering effects of statins
Sorrentino, S. A., & Landmesser, U. (2005) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-005-0031-1 · Cited by 31
Effect of preoperative statins in patients without coronary artery disease who undergo cardiac surgery
Tabata, M., Khalpey, Z. I., Cohn, L. H., Chen, F. Y., Bolman, R. M., III, & Rawn, J. D. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2008.03.061 · Cited by 27
The Endothelium – the Cardiovascular Health Barometer
Herrmann, J., & Lerman, A. (2008) · Herz · doi:10.1007/s00059-008-3088-2 · Cited by 28
Angiotensin II Type 1 Receptor Expression in Polymorphonuclear Leukocytes From High-Risk Subjects: Changes After Treatment With Simvastatin
Marino, F., Guasti, L., Cosentino, M., Ferrari, M., Rasini, E., Maio, R. C., Cimpanelli, M. G., Cereda, E., Crespi, C., Simoni, C., et al. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31803d35ce · Cited by 27
Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo
Ohkawara, H., Ishibashi, T., Saitoh, S.-I., Inoue, N., Sugimoto, K., Kamioka, M., Uekita, H., Kaneshiro, T., Ando, K., Takuwa, Y., et al. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq221 · Cited by 27
A peri‐operative statin update for non‐cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non‐surgical) patients
Biccard, B. M. (2007) · Anaesthesia · doi:10.1111/j.1365-2044.2007.05264.x · Cited by 26
The role of statins in endothelial dysfunction in hypertension
Sarkar, K., Sinha, A. K., & Mehta, J. L. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231401.87232.71 · Cited by 26
Analysis of antihypertensive effects of statins
Milionis, H. J., Liberopoulos, E. N., Elisaf, M., & Mikhailidis, D. P. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0032-4 · Cited by 26
Effect of pitavastatin on experimental choroidal neovascularization in rats
Sagara, N., Kawaji, T., Takano, A., Inomata, Y., Inatani, M., Fukushima, M., & Tanihara, H. (2007) · Experimental Eye Research · doi:10.1016/j.exer.2007.02.005 · Cited by 26
LDL cholesterol as a novel risk factor for contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention
Liu, Y.-H., Liu, Y., Chen, J., Zhou, Y., Chen, Z., Yu, D., Luo, J., Li, H., He, Y., Ye, P., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.022 · Cited by 25
Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Chyrchel, M., Rakowski, T., Rzeszutko, Ł., Legutko, J., Dziewierz, A., Dubiel, J. S., & Dudek, D. (2006) · PubMed · Cited by 25
Pharmacological Interventions to Prevent Vascular Endothelial Dysfunction: Future Directions
Balakumar, P., Koladiya, R. U., Ramasamy, S., Rathinavel, A., & Singh, M. (2008) · Eisei kagaku · doi:10.1248/jhs.54.1 · Cited by 24
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study
Bang, C. N., Gislason, G., Greve, A. M., Torp-Pedersen, C. T., Køber, L., & Wachtell, K. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312462804 · Cited by 23
Endothelial function in conduit and resistance arteries in men with coronary disease
Agewall, S., Henareh, L., & Kublickiene, K. R. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.03.025 · Cited by 23
Statins: potent vascular anti-inflammatory agents
Liao, J. K. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00375.x · Cited by 23
A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV
Hays, A. G., Schär, M., Barditch‐Crovo, P., Bagchi, S., Bonanno, G., Meyer, J., Afework, Y., Streeb, V., Stradley, S., Kelly, S., et al. (2021) · AIDS · doi:10.1097/qad.0000000000002845 · Cited by 23
COVID-19: Sleep, Circadian Rhythms and Immunity – Repurposing Drugs and Chronotherapeutics for SARS-CoV-2
Giri, A., Srinivasan, A., & Sundar, I. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.674204 · Cited by 23
Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
Bang, C. N., Greve, A. M., Boman, K., Egstrup, K., Gohlke-Baerwolf, C., Køber, L., Nienaber, C. A., Ray, S. G., Rossebø, A. B., & Wachtell, K. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.01.026 · Cited by 22
Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes
Sun, Y., Qi, G., Gao, Y. J., Zhang, H., Pang, X., Zhao, W., & Zhang, Z. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70452-9 · Cited by 21
Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury After Cardiac Catheterization
Yang, Y., Wu, Y., & Hu, Y.-Z. (2015) · Medicine · doi:10.1097/md.0000000000001226 · Cited by 21
Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives
Boushra, N. N., & Muntazar, M. (2006) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03022882 · Cited by 21
Do Statins Lower Blood Pressure?
Mangat, S., Agarwal, S., & Rosendorff, C. (2007) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248407300380 · Cited by 21
Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury.
Korybalska, K., Kawka, E., Bręborowicz, A., & Witowski, J. (2012) · PubMed · Cited by 19
Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID‐19; a retrospective cohort study
Aghajani, M. H., Moradi, O., Tehrani, H. A., Amini, H., Pourheidar, E., Hatami, F., Rabiei, M. M., & Sistanizad, M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14434 · Cited by 17
A Review of Perioperative Statin Therapy for Noncardiac Surgery
Skrlin, S. M., & Hou, V. W. (2010) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253210386387 · Cited by 17
Current role of statins in the treatment of essential hypertension
Kostapanos, M. S., Milionis, H. J., & Elisaf, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.491512 · Cited by 17
RhoA-dependent PAI-1 gene expression induced in endothelial cells by monocyte adhesion mediates geranylgeranyl transferase I and Ca2+ signaling
Sakamoto, T., Ishibashi, T., Sugimoto, K., Sakamoto, N., Ohkawara, H., Niinuma, M., Nagata, K., Kamioka, M., Sugimoto, N., Watanabe, A., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.036 · Cited by 16
Beneficial Effect of Atorvastatin on Left Ventricular Remodeling in Spontaneously Hypertensive Rats
Kang, L., Ge, C.-J., & Hu, S. (2007) · Pharmacology · doi:10.1159/000103251 · Cited by 16
Effects of statin therapy on vascular dysfunction
Aikawa, M. (2004) · Coronary Artery Disease · doi:10.1097/01.mca.0000132583.04711.47 · Cited by 16
Effect of pravastatin on impaired endothelium-dependent relaxation induced by lysophosphatidylcholine in rat aorta1
Deng, H., & Xiong, Y. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00013.x · Cited by 16

Authors: Wassmann, S., Faul, A., Hennen, B., Scheller, B., Böhm, M., & Nickenig, G.
Affiliations: Universitätsklinikum des Saarlandes (DE)
From Medizinische Klinik und Poliklinik, Innere Medizin III, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.
ORCID: Wassmann, Sven
Scheller, Bruno
Nickenig, Georg
Venue: Circulation Research
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2003-10-31
Volume: 93
Issue: 9
Pages: e98-103
ISSN: 0009-7330 (ISSN-L)
1524-4571
DOI: 10.1161/01.res.0000099503.13312.7b
OpenAlex: W2166462038
Cited by: 177
References: 41
Citations by year: 2026: 2 · 2025: 2 · 2023: 5 · 2022: 1 · 2021: 6 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 8 · 2013: 5 · 2012: 11
FWCI: 16.72
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation Research (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Deutsche Forschungsgemeinschaft
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: pravastatin, statins, coronary endothelial function, endothelial dysfunction, acetylcholine-induced vasoconstriction, nitroglycerin, coronary blood flow reserve, adenosine, stable angina, hypercholesterolemia, coronary vasculature, lipid-lowering therapy
MeSH terms: Aged, Angina Pectoris, Blood Flow Velocity, Blood Pressure, C-Reactive Protein, Coronary Circulation, Coronary Vessels, Double-Blind Method, Endothelium, Vascular, Female, Heart Rate, Humans, Hydroxymethylglutaryl CoA Reductases, Lipids, Male, Middle Aged, Prospective Studies, Time Factors, Vascular Patency, Vasodilation, Vasodilator Agents, Coronary Angiography, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks